Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-02-26 | Reverse | 1:72 |
AEON Biopharma, Inc., founded in 2012 and based in Newport Beach, CA, develops botulinum toxins like ABP-450 for treating migraines, dystonia, and gastroparesis.

ABP-450 is a botulinum toxin complex in clinical development as a potential biosimilar to BOTOX®, targeting various medical conditions with an initial focus on the neurosciences market.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
CING | $5.33 | COMPARE |
CLNN | $4.23 | COMPARE |
MRKR | $1.37 | COMPARE |
CLRB | $2.53 | COMPARE |
BOLT | $3.81 | COMPARE |
MBIO | $0.54 | COMPARE |
OSRH | $0.12 | COMPARE |